The European Commission has approved the Rhapsido drug, the first oral targeted treatment for the skin disease, allowing it to be taken twice daily without lab monitoring. The drug is also the first time the drug has been approved for the treatment. The company has stated that it offers a unique approach to treateneniveive treatment.